Denosumab 60 MG/ML Prefilled Syringe
Denosumab Dose: 60 milligrams, subcutaneous injection, every 6 months (twice a year)

Zoledronic Acid 5Mg/Bag 100Ml Inj
Zoledronic acid will be 5 milligrams, Intravenous injection, once a year

Thalassemia Majors (Beta-Thalassemia Major)

Osteoporosis

Denosumab 60 MG/ML will be administered to 20 patients with b-thalassemia major

Denosumab 60 MG/ML Prefilled Syringe

Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major

Zoledronic Acid 5Mg/Bag 100Ml Inj

National Center for Cancer Care & Research (NCCCR)

Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis

Denosumab Versus Zoledronic Acid for Patients With Beta-Thalassemia Major-Induced Osteoporosis

Number of patients with a 50 percent or greater reduction in type-1 collagen carboxy telopeptide from the baseline

Number of patients with a 50 percent or greater improvement in Dual-energy X-ray absorptiometry scan from the baseline

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Hamad Medical Corporation

Participants ambulatory in normobaric hypoxia with standardised nutritional intake

Participants are on bed rest in normobaric hypoxia with standardised nutritional intake

Participants are on bed rest in normobaric normoxia with standardised nutritional intake

Hypoxia

Bone Resorption

21 days confinement in normobaric hypoxic (FiO2 = 14%)

Participants hava a standardized activity level throughout the intervention

Ambulatory

21 days confinement in normobaric normoxic (FiO2 = 21%) environment

Normoxia

Participants remain on supine bed rest throughout the intervention

Bed Rest

Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant

Standardised nutritional intake

Planetary Habitat Simulation: Bone Metabolism Studies

Planetary Habitat Simulation: The Combined Effects of Bed Rest and Normobaric Hypoxia Upon Bone and Mineral Metabolism (WP3)

assessed before (day -5), on days 2, 10 and 21 of the intervention and at the 14-day follow-up visit (40 days after 1st measurement) using pQCT scans of the calf and thigh.

assessed from 24hr urine collections taken before (day -5), on days 1,2,3,4,8,10,12,14,16,18, and 21 of the intervention and on the 2nd, 3rd, and 4th day after each intervention period (last urine collection 30 days after first measurement)

assessed from 24hr urine collections taken before (day -5), on days 1,2,3,4,8,10,12,14,16,18, and 21 of the intervention and on the 2nd, 3rd, and 4th day after each intervention period (last urine collection 31 days after first measurement)

assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention. Last sample point made 26 days after baseline sample

Elizabeth Simpson

University of Nottingham

Jozef Stefan Institute

DLR German Aerospace Center

KTH Royal Institute of Technology

European Commission

Assess the Effects of a the 90-day Oral TS Study Regimen on PSA, IPSS, Haemoglobin and Haematocrit, and to Assess Adverse and Serious Adverse Events.

Andriol Testocaps

Camry Medical Centre

Frontier Medical Associates (Ubi) Pte Ltd

Everhealth Medical Centre

Frontier Medical Associates (Buangkok Cresent) Pte Ltd

Frontier Medical Associates (AMK) Pte Ltd

EJ Tan Clinic & Surgery

Everhealth Family Clinic & Surgery

Bukit Batok Medical Clinic

Princeton Family Clinic Pte Ltd

The Edinburgh Clinic

Frontier Medical Associates (Woodlands) Pte Ltd

Frontier Medical Associates (Yishun) Pte Ltd

The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes (T2DM)

The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes: OTEST

The primary aim is to assess the effect of oral Testosterone Supplementation on percent change in HbA1c in Type 2 Diabetes Mellitus Chinese males in Singapore over a 90-day study period.

The secondary aim is to assess the effects of site, eugonadism and hypogonadism, and the prognostic relevance of baseline levels of HbA1c, total testosterone, PSA, IPSS, haemoglobin and haematocrit on 90-day change and percent change from baseline in HbA1c under the study Testosterone Supplementation regimen.

hypogonadism/phosphatase

Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis

Planetary Habitat Simulation: Bone Metabolism Studies

The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes (T2DM)

Täydellisin lääketieteellinen tietokanta tieteen tukemana